Fair enough. Not to split hairs but on the CR on 20/6/2020 they were targeting three indications, and they raised at $1.40 per share. Just over a year later they had another indication and the chance to raise more funds at a 34% higher SP and give more breathing room if the FDA didn't approve Trof, whilst dialling back the discount for the newly issued shares a bit. It seems like a sensible decision to me, but it's your opinion which is valid.
Neuren-successfully-completes-20m-capital-raising.pdf (neurenpharma.com)
Even if we had enough funds to complete those trials management had a fair expectation of NNZ-2591 could be, and the fact the market would look at their cash position and assume a CR would be needed (even if they could scrape by) and, by extension, the SP could be driven lower than fair value at that time. Any company I am looking to invest in which has a poor cash flow position I always have a huge margin of safety on, because I presume CR's will be priced poorly to reflect the utter contempt most companies show towards their retail shareholders.
- Forums
- ASX - By Stock
- NEU
- Possibly a new direction?
Possibly a new direction?, page-27
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.65 |
Change
0.000(0.00%) |
Mkt cap ! $1.744B |
Open | High | Low | Value | Volume |
$13.70 | $13.76 | $13.56 | $3.689M | 270.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 37 | $13.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.66 | 1132 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 37 | 13.600 |
1 | 1767 | 13.580 |
2 | 699 | 13.570 |
1 | 1767 | 13.560 |
1 | 1767 | 13.530 |
Price($) | Vol. | No. |
---|---|---|
13.660 | 1132 | 2 |
13.690 | 2466 | 3 |
13.710 | 1767 | 1 |
13.740 | 1767 | 1 |
13.750 | 300 | 2 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |